CN115916975A - 靶向mitf基因的核酸分子及其用途 - Google Patents
靶向mitf基因的核酸分子及其用途 Download PDFInfo
- Publication number
- CN115916975A CN115916975A CN202180042234.0A CN202180042234A CN115916975A CN 115916975 A CN115916975 A CN 115916975A CN 202180042234 A CN202180042234 A CN 202180042234A CN 115916975 A CN115916975 A CN 115916975A
- Authority
- CN
- China
- Prior art keywords
- nucleic acid
- acid molecule
- short activating
- mitf
- activating nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
提供了一种双链核酸分子,特别是一种小激活核酸分子,所述小激活核酸分子可以是靶向MITF基因的核酸分子,其至少包含第一寡核苷酸链。还提供了包含小激活核酸分子的组合物或制剂及其用途。使用所述小激活核酸分子或含有所述小激活核酸分子的组合物或制剂可激活或上调MITF基因在细胞中的表达,治疗与MITF蛋白表达不足或减少相关的疾病或状况。
Description
PCT国内申请,说明书已公开。
Claims (28)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020105241391 | 2020-06-10 | ||
CN202010524139 | 2020-06-10 | ||
PCT/CN2021/091834 WO2021249064A1 (zh) | 2020-06-10 | 2021-05-06 | 靶向mitf基因的核酸分子及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115916975A true CN115916975A (zh) | 2023-04-04 |
Family
ID=78845221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180042234.0A Pending CN115916975A (zh) | 2020-06-10 | 2021-05-06 | 靶向mitf基因的核酸分子及其用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230220389A1 (zh) |
EP (1) | EP4166668A4 (zh) |
JP (1) | JP2023529398A (zh) |
KR (1) | KR20230022167A (zh) |
CN (1) | CN115916975A (zh) |
AU (1) | AU2021288166A1 (zh) |
CA (1) | CA3179261A1 (zh) |
WO (1) | WO2021249064A1 (zh) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102429894B (zh) * | 2011-12-07 | 2013-03-13 | 中国药科大学 | 氟西汀治疗色素脱色疾病的用途 |
CN106032532A (zh) * | 2015-03-17 | 2016-10-19 | 中国医学科学院北京协和医院 | 一种小激活rna及其制备方法和应用 |
WO2016170348A2 (en) * | 2015-04-22 | 2016-10-27 | Mina Therapeutics Limited | Sarna compositions and methods of use |
KR101841748B1 (ko) * | 2016-02-18 | 2018-05-08 | (주)케어젠 | 멜라닌 생성 촉진 활성을 나타내는 펩타이드 및 이의 용도 |
KR20200140377A (ko) * | 2018-04-10 | 2020-12-15 | 락티젠 세러퓨틱스 | 신규 작은 활성 rna |
-
2021
- 2021-05-06 US US18/000,838 patent/US20230220389A1/en active Pending
- 2021-05-06 JP JP2022575306A patent/JP2023529398A/ja active Pending
- 2021-05-06 CN CN202180042234.0A patent/CN115916975A/zh active Pending
- 2021-05-06 KR KR1020227041508A patent/KR20230022167A/ko unknown
- 2021-05-06 AU AU2021288166A patent/AU2021288166A1/en active Pending
- 2021-05-06 WO PCT/CN2021/091834 patent/WO2021249064A1/zh unknown
- 2021-05-06 EP EP21823138.9A patent/EP4166668A4/en active Pending
- 2021-05-06 CA CA3179261A patent/CA3179261A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2021288166A1 (en) | 2023-01-19 |
WO2021249064A1 (zh) | 2021-12-16 |
EP4166668A4 (en) | 2024-07-17 |
JP2023529398A (ja) | 2023-07-10 |
CA3179261A1 (en) | 2021-12-16 |
EP4166668A1 (en) | 2023-04-19 |
US20230220389A1 (en) | 2023-07-13 |
KR20230022167A (ko) | 2023-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110959042B (zh) | 一种新型小激活rna | |
US9637747B2 (en) | Inducible gene expression composition for using eukaryotic pol-2 promoter-driven transcription in prokaryotes and the applications thereof | |
CN110123828B (zh) | Pralr的抑制剂在制备治疗耐紫杉醇卵巢癌的药物中的应用 | |
CN112996913B (zh) | 寡聚核酸分子及其应用 | |
CN110678549B (zh) | 一种激活p21基因表达的方法 | |
CN113260702B (zh) | 寡聚核酸分子及其在急性间歇性卟啉症治疗中的应用 | |
CN115916975A (zh) | 靶向mitf基因的核酸分子及其用途 | |
KR20230133311A (ko) | CD73 mRNA 및 CD73 단백질 발현의 양을 감소시키는올리고뉴클레오티드 | |
WO2021000928A1 (zh) | 激活atoh1基因的寡聚核酸分子及其应用 | |
CN112912501B (zh) | 寡核苷酸分子及其在肿瘤治疗中的应用 | |
CN111808954B (zh) | lncRNA及其在疾病中的应用 | |
CN111763735B (zh) | 肿瘤差异表达基因及其应用 | |
WO2021052470A1 (zh) | 用于治疗血小板减少症的核酸分子及其应用 | |
CA3225778A1 (en) | Methods of treating skin cancer with carboxypeptidase vitellogenic like (cpvl) inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40087139 Country of ref document: HK |